On 16 June 2020, ResApp signed a two-year, non-exclusive commercial software licensing agreement with Phenix Health Pty Ltd, Australia based virtual super clinic, to use ResApp’s acute respiratory diagnostic test, ResAppDx-EU, in Phenix’s telehealth smartphone app.

For the full article you can visit: https://kalkinemedia.com/au/covid-19/government-urged-to-continue-mbs-funded-telehealth-services-resmed-resapp-to-reap-the-benefits